Effects of low-dose atrial natriuretic peptide infusion on cardiac surgery-associated acute kidney injury: A multicenter randomized controlled trial

What Was Tested

Researchers studied ANP (Atrial Natriuretic Peptide) in this randomized controlled trial publication.

Who Took Part

PubMed indexes the participants as older adults, both men and women.

The Japanese trial for AKI in Post-cardiovascular surgery patients by ANP (JAPAN) was a prospective, multicenter, randomized, double-blind, placebo-controlled study conducted in 11 hospitals in Japan.

The secondary end points were a need for renal replacement therapy, the lengths of intensive care unit and hospital stays, and medical costs incurred over the 90-day follow-up.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and multicenter.

Random assignment meant chance, not the researchers, decided who got ANP (Atrial Natriuretic Peptide) and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on ANP (Atrial Natriuretic Peptide), so expectations could not easily colour the readings.

Some participants received a placebo instead of ANP (Atrial Natriuretic Peptide), giving a reference point.

Running at several centres spread the ANP (Atrial Natriuretic Peptide) study over different clinics and patient groups.

The primary end point was a change in renal function.

What Was Measured

PubMed files the paper under topics including Acute Kidney Injury, Atrial Natriuretic Factor, Cardiac Surgical Procedures, Health Care Costs, Intensive Care Units, Japan and Kidney Function Tests.

The authors tagged it with the keywords Atrial natriuretic peptide, Cardiac surgery, Medical costs and Renal function.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of ANP (Atrial Natriuretic Peptide).

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (Journal of critical care), a journal based in United States.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.